← All trials
NCT06204120
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 25, 2022
- Primary completion
- Jul 4, 2023
- Completion date
- Jul 4, 2023
- First posted
- Jan 12, 2024
- Last posted
- Jan 12, 2024
- Enrollment
- 150
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Luye PharmaLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.